BRAIN-TARGETED NANO-DRUG DELIVERY FOR THE TREATMENT OF PARKINSON'S DISEASE
Parkinson’s Disease affects 2% to 3% of overall individuals aged 65 years or older worldwide and is considered to be the second most common age-related neurodegenerative disease. Neuropathologic features of Parkinson’s Disease attributes to a loss of pigmented dopaminergic neurons in the substantia...
Wedi'i Gadw mewn:
| Prif Awduron: | , , , |
|---|---|
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Atatürk University
2024-06-01
|
| Cyfres: | Current Research in Health Sciences |
| Pynciau: | |
| Mynediad Ar-lein: | https://dergipark.org.tr/tr/download/article-file/3549566 |
| Tagiau: |
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|